Get the Stockscreener App
9.56
0.74%
0.07
Pre-market:
9.30
-0.26
-2.72%
Contineum Therapeutics Inc stock is traded at $9.56, with a volume of 147.93K.
It is up +0.74% in the last 24 hours and down -13.41% over the past month.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
See More
Previous Close:
$9.49
Open:
$9.46
24h Volume:
147.93K
Relative Volume:
0.82
Market Cap:
$349.22M
Revenue:
-
Net Income/Loss:
$-35.46M
P/E Ratio:
-22.66
EPS:
-0.4218
Net Cash Flow:
$-34.00M
1W Performance:
-16.36%
1M Performance:
-13.41%
6M Performance:
+150.92%
1Y Performance:
-30.57%
1-Day Range:
$9.25
$9.69
1-Week Range:
$9.25
$11.73
52-Week Range:
$3.35
$13.62
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
9.56 | 346.66M | 0 | -35.46M | -34.00M | -0.4218 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics stock downgraded by Morgan Stanley on IPF drug concerns - Investing.com
Contineum Therapeutics stock drops as company prices upsized $90 million offering - MSN
What sentiment indicators say about Contineum Therapeutics Inc. stockSector Performance Review & Explosive Capital Gains - ulpravda.ru
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? - Finviz
Lorrain, Contineum Therapeutics CSO, sells $51k in stock - Investing.com India
Lorrain, Contineum Therapeutics CSO, sells $51k in stock By Investing.com - Investing.com Australia
Contineum Therapeutics announces proposed $75M public offering - MSN
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - MSN
Contineum Therapeutics Reports Increased R&D Investment Amid Losses - MSN
Contineum Therapeutics, Inc.(NasdaqGS: CTNM) added to NASDAQ Biotechnology Index - marketscreener.com
Aug Sentiment: Why Contineum Therapeutics Inc. stock is seen as undervaluedInflation Watch & Reliable Intraday Trade Alerts - Улправда
Contineum Therapeutics (NASDAQ:CTNM) Raised to Hold at Wall Street Zen - MarketBeat
Why analysts remain bullish on Contineum Therapeutics Inc. stockMarket Movers & Expert Approved Trade Ideas - Улправда
Why retail investors favor Contineum Therapeutics Inc. stockJuly 2025 Summary & Daily Chart Pattern Signals - Улправда
Why Contineum Therapeutics Inc. stock attracts high net worth investorsWeekly Trend Report & Free Long-Term Investment Growth Plans - Улправда
How risky is Contineum Therapeutics Inc. stock now2025 Trading Volume Trends & Low Risk Entry Point Tips - Улправда
Why Contineum Therapeutics Inc. stock is seen as undervaluedWeekly Profit Recap & Free Technical Pattern Based Buy Signals - Улправда
What risks investors should watch in Contineum Therapeutics Inc. stockOptions Play & Weekly Setup with ROI Potential - Улправда
Published on: 2025-12-19 19:15:06 - Улправда
Why Contineum Therapeutics Inc. stock remains undervaluedEntry Point & Smart Money Movement Alerts - DonanımHaber
Aug Breakouts: Why Contineum Therapeutics Inc. stock is seen as undervalued2025 Earnings Impact & Capital Efficient Trading Techniques - Улправда
Published on: 2025-12-19 11:46:29 - Улправда
Can Contineum Therapeutics Inc. stock deliver strong Q4 earnings2025 Geopolitical Influence & Safe Entry Point Identification - DonanımHaber
Contineum Therapeutics Earnings Notes - Trefis
EBITDA per share of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView — Track All Markets
Great Week for Contineum Therapeutics, Inc. (NASDAQ:CTNM) Institutional Investors After Losing 5.3% Over the Previous Year - 富途牛牛
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Contineum Therapeutics Inc trading resumes - MSN
Contineum price target lowered to $22 from $25 at RBC Capital - MSN
Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering - marketscreener.com
Contineum prices upsized public offering of common stock at $12.25 per share - Investing.com Nigeria
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Contineum prices upsized public offering of common stock at $12.25 per share By Investing.com - Investing.com South Africa
Contineum Therapeutics prices upsized $90 million public offering at $12.25 per share - marketscreener.com
Contineum Therapeutics (NASDAQ: CTNM) sets price for upsized $90.0M offering - Stock Titan
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
Contineum Therapeutics launches $75 million public offering of stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics launches $75 million public offering of stock - Investing.com
Contineum Therapeutics falls on planned $75 million share sale - TradingView — Track All Markets
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
ETFs Investing in Contineum Therapeutics, Inc. Stocks - TradingView — Track All Markets
Contineum Therapeutics, Inc. (NASDAQ:CTNM) institutional owners may be pleased with recent gains after 16% loss over the past year - simplywall.st
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):